Study Evaluating Biomarkers in Patients With Colorectal Cancer and Native KRAS Treated With Chemotherapy + Cetuximab

Colorectal Cancer Clinical Trial

— POSIBA  

Official title:

Single-Arm, Multicenter, Prospective, Phase 2 Study for the Evaluation of Biomarkers in Patients With Advanced &/or Metastatic Colorectal Cancer With Wild Type KRAS Treated Biweekly With Chemotherapy and Cetuximab as First-Line Treatment

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01276379
• Other study ID #: GEMCAD-1002
• Secondary ID: 2010-019236-12
• Status: Completed
• Phase: Phase 2
• Start date: January 2011
• Est. completion date: December 21, 2017

Study information

• Verified date: June 2021
• Source: Grupo Espanol Multidisciplinario del Cancer Digestivo
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Advanced colorectal cancer (ACRC) is a heterogeneous disease and classification of patients is nowadays inefficient. Roughly twenty per cent of patients present with favorable figures (less than 4 liver nodules and less than 5 cm) and are suitable for local treatments (surgery or local-ablative therapies). Additionally, 10-15% of patients have poor performance status (PS >2) or are severe disabled due to geriatric syndromes or/and co-morbid diseases that preclude any treatment strategies than best supportive care alone. The rest of patients (fit patients not suitable for radical treatments) constitute the population of patients treated with palliative therapies. Despite of it not all these patients have the same prognosis. Patients with PS 0,1 and levels of LDH <ULN (Intermediate-risk patients) have better PFS and OS irrespective of therapy in all randomized clinical trials (de Gramont et al, JCO 2000; Douillard et al, Lancet 2000; Koopman et al, 2007).

CRYSTAL trial shows a benefit in PFS (1.5 months) in RASWT of FOLFIRI plus cetuximab compared with FOLFIRI alone. Nowadays the selection of patients for cetuximab treatment is based on mutational status of KRAS, which allow to select those patients who will not respond to therapy. Other surrogate markers of activity should be also evaluated. Our hypothesis is that the suggested biomarkers will allow the selection of the patients who will benefit the most from the biweekly cetuximab treatment.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 221
• Est. completion date: December 21, 2017
• Est. primary completion date: March 15, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Male or female, age = 18 years

• Able to sign an informed consent form

• Advanced and/or metastatic colorectal cancer

• Colorectal cancer with KRAS wild type genotype

• At least one unidimensionally measurable lesion according to RECIST criteria (1.1 revised) (to be assessed = 28 days prior to the study treatment)

• All patients with the following features will be included:

1. Progression free survival > 6 months after adjuvant treatment +/- radiotherapy

2. "De novo" diagnosis of the disease

• Performance ECOG status of 0-2

• Life expectancy = 3 months

• Adequate bone marrow function: neutrophils =1,5 x 10^9/L; platelets = 100 x 10^9/L; hemoglobin =9 g/dL.

• Adequate liver, renal and hematological function as follows:

1. Adequate liver function: SGOT and SGPT 2.5 x ULN (5 x ULN in case of hepatic metastasis). Total bilirubin < 1,5 x ULN. Alkaline phosphatase 2,5 x LSN (5 x ULN if hepatic metastasis or 10 x ULN if bone metastasis)

2. Creatinine clearance or creatinine clearance during 24 hours = 50 mL/min

3. Magnesium = LLN, calcium = LLN

Exclusion Criteria:

• PS > 2 or elderly patients with fragility criteria

• Previous surgery for metastasis

• Previous systemic treatment for the metastatic colorectal cancer

• Previous treatment with antibodies anti-EGFR or treatment with small-molecule EGFR tyrosine kinase inhibitors or EGFR signal transduction inhibitors. Subjects who suspend their first dose due to a reaction to the infusion can participate

• Central nervous system metastasis (except: treated subjects with asymptomatic CNS metastasis who have not received steroids within the 30 days prior to inclusion)

• Prior malignant tumor in the last 5 years, except: basal cell carcinoma of the skin or pre-invasive cervical cancer

• Unresolved toxicities from a prior systemic treatment which do not qualify the patient for inclusion

• Presence of peripheral neuropathy (degree > 1 in the ctc version 3.0) and serious nonhealing wound, ulcer, or bone fracture

• Hormonal treatment, immunotherapy or experimental or approved antibodies/proteins = 30 days before the inclusion

• Uncontrolled serious cardiovascular disease or: congestive cardiac failure NYHA lll or lV, unstable angina pectoris, myocardial infarction precedents in the past 12 months, significant arrhythmias

• Interstitial pneumonitis or pulmonary fibrosis precedents, or interstitial pneumonitis or pulmonary fibrosis signs on the thoracic CT-scan

• Treatment for systemic infection within the 14 days prior to treatment

• Acute/subacute intestinal occlusion and/or active inflammatory bowel disease or any other bowel disease producing chronic diarrhea

• Precedent of Gilbert's syndrome or dihydropyrimidine dehydrogenase deficiency

• Precedent of any disease which can increase the risks associated to the participation in the study or interfere in the study results

• Known positive test for the following infections: HIV, Hepatitis C + abnormal liver enzymes values, active chronic Hepatitis B (except Hepatitis C seropositive with normal liver enzymes)

• All concurrent diseases which can increase the toxicity risk

• The individual presents a disorder of any kind which jeopardizes their ability to give their written consent form and/or fulfill the study procedures

• Any investigational agent within 30 days before enrolment

• Pregnant or breastfeeding woman, or planning to get pregnant within the 6 months after treatment

• Surgery (excluding the diagnostic biopsy or placing of a central venous catheter)

• Woman or man of childbearing potential not consenting to use adequate contraceptive precautions during the study and 6 months after de last administration for women, and 1 month for men

• Unability to fulfill the study requirements by the patients

• Psychological, family, sociological or geographical conditions that may interfere with the fulfillment of the study protocol and the follow-up calendar

Related Conditions & MeSH terms

• Colorectal Cancer
• Colorectal Neoplasms

Intervention

Drug:
• FOLFIRI (m)
FOLFIRI (m) chemotherapy will be administered on day 1 of each 14-days-cycle. The administered doses will be: Irinotecan 180 mg/m2 in infusion i.v., 120 minutes, on day 1 of each cycle. l-Leucovorin 200 mg/m2 (or d,l-leucovorin 400 mg/m2), in infusion i.v., 120 minutes, on day 1. One bolus i.v. (2-4 minutes) of 400 mg/m2 of 5-FU on day 1. 5-FU in continuous infusion (2400 mg/m2) administered through an ambulatory pump during 46-48 hours.
• FOLFOX-6 (m)
FOLFOX6 (m) chemotherapy will be administered on day 1 of each 14-days-cycle. The administered doses will be: Oxaliplatin 85 mg/m2 in infusion i.v., 120 minutes, on day 1 of each cycle. l-Leucovorin 200 mg/m2 (or d,l-leucovorin 400 mg/m2) in infusion i.v., 120 minutes, on day 1. One bolus i.v. (2-4 minutes) of 400 mg/m2 of 5-FU on day 1. 5-FU in continuous infusion (2400 mg/m2) administered through an ambulatory pump during 46-48 hours.
• Cetuximab
- 500 mg/m2 i.v. Every 2 weeks.

Locations

Country	Name	City	State
Spain	Complejo Hospitalario Universitario de Albacete	Albacete
Spain	Hospital Infanta Cristina de Badajoz	Badajoz
Spain	Hospital de Barbastro	Barbastro
Spain	Hospital Clínic de Barcelona	Barcelona
Spain	Hospital General Yagüe	Burgos
Spain	Hospital San Pedro de Alcántara	Cáceres
Spain	Hospital Sant Jaume de Calella	Calella
Spain	Hospital Provincial de Castellón	Castelló de la Plana	Castellón
Spain	Hospital General Universitario de Elche	Elche
Spain	Hospital de Jaén	Jaén
Spain	Hospital Universitario de Gran Canaria Dr. Negrín	Las Palmas de Gran Canaria
Spain	Hospital Universitari Arnau de Vilanova de Lleida	Lleida
Spain	Fundación Jimenez Díaz	Madrid
Spain	Hospital de Móstoles	Madrid
Spain	Hospital Universitario la Paz	Madrid
Spain	Hospital de Mataró	Mataró
Spain	Hospital Son Espases	Palma	Malllorca
Spain	Hospital Son Llàtzer	Palma	Mallorca
Spain	Clínica Universitaria de Navarra	Pamplona
Spain	Hospital de Navarra	Pamplona
Spain	Hospital Sant Joan de Reus	Reus	Tarragona
Spain	Hospital de Sagunto	Sagunto
Spain	Mutua de Terrassa	Terrassa
Spain	Hospital Virgen de la Salud	Toledo
Spain	Instituto Valenciano de Oncología	Valencia
Spain	Hospital Clínico Universitario Lozano Blesa	Zaragoza
Spain	Hospital Miguel Servet	Zaragoza

Sponsors (1)

Lead Sponsor	Collaborator
Grupo Espanol Multidisciplinario del Cancer Digestivo

Country where clinical trial is conducted

Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression Free Survival	Measurements according to RECIST 1.1 criteria (Response Evaluation Criteria in Solid Tumors). Main techniques: CT-scan. Two groups will be defined based on the score built from the proposed clinical variables and biomarkers. Instead of a binomial distribution, a Log-rank method has been used to calculate the sample size in order to include all the incidents during the follow-up. Expecting a minimum 20% difference (60 vs. 40%) on PFS at 12 months between groups and with the following assumptions: Alpha error (bilateral): 5% Beta error: 20% Results are reported by subgroups to compare outcome measure according to BRAF mutation. All patients belong to same treatment/study arm.	4 years
Secondary	Overall Survival	Measured as time in months from start of study treatment to death or lost to follow up.; Results are reported by subgroups to compare outcome measure according to BRAF mutation. All patients belong to same treatment/study arm.	4 years
Secondary	Response Duration	Duration of the partial or total response to the treatment. Evaluation and classification according to RECIST 1.1 criteria (Response Evaluation Criteria in Solid Tumors)	4 years
Secondary	Frequency of Adverse Events	Frequency and type of adverse events (AEs). AEs were coded according to NCI CTCAE V3.0 and classified by frequency, relatedness to study treatment (related/not related) and severity (Grade).; Severity ranges from grade 1 (low intensity) to Grade 5 (max. intensity, death)	4 years
Secondary	Secondary Biomarkers Analysis	The secondary biomarkers in serum and tumoral tissue will be analysed in order to predict the acquired resistance.	4 years
Secondary	Tumoral Response	Measurements according to RECIST 1.1 criteria (Response Evaluation Criteria in Solid Tumors). Main techniques: CT-scan. Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR Results are reported by subgroups to compare outcome measure according to BRAF mutation. All patients belong to same treatment/study arm.	4 years

External Links

•   GEMCAD group